Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion

NCT03802630 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

450

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated by sponsor due to increased incidences of AEs of special interest (intraocular inflammation including retinal vasculitis and retinal vascular occlusion), in patients dosed brolucizumab 6mg every 4 weeks beyond 3 initial doses

Conditions

Branch Retinal Vein Occlusion

Interventions

DRUG: Brolucizumab 6 mg
DRUG: Aflibercept 2 mg
OTHER: Sham injection

Sponsor

Novartis Pharmaceuticals